康复新联合雷贝拉唑、伊托必利治疗胃食管反流病疗效观察

详细信息

收稿日期: 2013-05-21

Received Date: 21 May 2013

摘要: [目的]探讨康复新联合雷贝拉唑治疗胃食管反流病的疗效、安全性。[方法]符合纳入标准的胃食管反流病患者130例,随机分为治疗组与对照组,各65例;治疗组给予康复新+雷贝拉唑+伊托必利,对照组给予雷贝拉唑+伊托必利,疗程均为8周;对2组治疗后临床疗效和安全性进行观察。[结果]治疗组胃食管反流病的临床症状缓解率、复发率均优于对照组。[结论]康复新联合雷贝拉唑是治疗胃食管反流病的理想药物,安全可靠。
- 胃食管反流 /
- 康复新 /
- 疗效观察

[1]	中华医学会消化病学分会胃肠动力组.胃食管反流病共识意见 (2007, 西安)[J].中华消化杂志, 2007, 27 (10):689-690.
[2]	FASS R, SIFRIM D.Management of heartburn not responding to proton pump inhibitors[J].Gut, 2009, 58:295-309.
[3]	MARREWIJK C J, MUJACKOVIC S, FRANSEN G A, et al.Effect and cost-effectiveness of step-up vessus step-down treatment with antiacid, H2-recepteor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (Diamond study):aprimary-carebased randomised controlled trial[J].Lancet, 2009, 17:215-225.
[4]	凃蕾, 侯晓华.胃食管反流病的病因和发病机制[J].现代消化及介入诊疗, 2011, 16 (1):37-41.
[5]	白班俊, 黄国美.康复新液治疗十二指肠巨大溃疡120例临床观察[J].华西药学杂志, 2011, 26 (4):399-400.